Citius Oncology, Inc. CTOR Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s common stock?
- Citius Oncology, Inc. (CTOR) reported common stock of 400M in Q1 2026.
- How has Citius Oncology, Inc.'s common stock changed year-over-year?
- Citius Oncology, Inc.'s common stock increased by 300.0% year-over-year, from 100M to 400M.
- What is the long-term trend for Citius Oncology, Inc.'s common stock?
- Over 3 years (2022 to 2025), Citius Oncology, Inc.'s common stock has grown at a 38.7% compound annual growth rate (CAGR), from 150M to 400M.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).